Bringing the Oncology Community Together

Biomarkers, Pathways, and Targeted Therapies®

Latest Biomarkers, Pathways, and Targeted Therapies® Articles View more >>
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD
Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD
An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents
Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents
The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain
Aduro BioTech Immunotherapy Duo Shows Promise in Pancreatic Cancer
Aduro BioTech Immunotherapy Duo Shows Promise in Pancreatic Cancer
The use of immunotherapy for pancreatic cancer has had limited exposure, but Aduro BioTech, Inc, has had phase II success with an approach in which two vaccines are administered. The vaccines, GVAX Pancreas and CRS-207, are administered to patients sequentially.
Partner Spotlight

Can Mouse Avatars Guide Cancer Treatment?

Dr Ralph de Vere White, from the UC Davis Comprehensive Cancer Center, writes about utilizing NSG mice to predict response to treatment.

Read more >>>

 
Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.